Integrated UHPLC-Q-exactive orbitrap HRMS and serum pharmacochemistry for the investigation of anti-hepatic fibrosis effect of Baoganning Decoction

作者：Kaili Deng, Min Li, Liangliang Xiang, Yuhua Wang, Yamei Li, Junya Wen, Yuanyuan Li, Shanshan Kuang, Jin Fu Wen, Chuying Zhou, Sha Huang, Zhiping Lv · 发表于：Phytomedicine · 年份：2025 · DOI：10.1016/j.phymed.2025.156363 · 被引用次数：11 · 研究领域：Liver physiology and pathology、Liver Disease Diagnosis and Treatment、Traditional Chinese Medicine Analysis

BACKGROUND: Early intervention in hepatic fibrosis (HF) is critical to reducing the risk of cirrhosis-related mortality and hepatocellular cancer. However, treating fibrosis has proven to be more challenging, with no approved anti-fibrotic therapies currently available for HF. Traditional Chinese medicines (TCMs) hold significant potential for the management of HF. PURPOSE: This study aims to propose a systematic approach for investigating the pharmacological basis of Baoganning (BGN) Decoction, providing empirical evidence to support future research on its targets and mechanisms of BGN. STUDY DESIGN: Ultrahigh-performance liquid chromatography coupled with high- resolution mass spectrometry (UPLC-HRMS) was employed to analyze the chemical composition of BGN. Key compounds were investigated using disease databases to predict relevant targets, followed by molecular docking and molecular dynamics simulations to explore molecular-level interactions. The efficacy and critical targets of BGN were validated through in vivo and in vitro experiments. METHODS: UPLC-HRMS was used to identify the chemical composition of the BGN, and serum pharmacology determined the active chemical constituents in rat plasma. Zebrafish, HSC-T6 cells, JS-1 cell line and mice served as experimental models to evaluate the antifibrotic effects of BGN. RESULTS: BGN demonstrated significant antifibrotic effect in vivo and in vitro models. A total of 757 compounds were identified in BGN, with 18 prototypical c...